已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study

离格 肝细胞癌 医学 立体定向放射治疗 放射外科 肿瘤科 放射治疗 放射科 内科学
作者
Seo Hee Choi,Byung Min Lee,Jina Kim,Do Young Kim,Jinsil Seong
出处
期刊:Journal of Hepatology [Elsevier]
卷期号:81 (1): 84-92 被引量:4
标识
DOI:10.1016/j.jhep.2024.03.003
摘要

Abstract

Background & Aims

Stereotactic ablative radiotherapy (SABR) has demonstrated curative potential with survival benefits in patients with oligometastatic disease (OMD). However, limited evidence exists regarding its use in oligometastatic hepatocellular carcinoma (HCC). We aimed to prospectively investigate the efficacy and safety of SABR in patients with oligometastatic HCC.

Methods

We enrolled patients with controlled primary HCC and one to five metastatic lesions amenable to SABR. The primary endpoint was treatment efficacy defined as overall survival (OS) and progression-free survival (PFS). The secondary endpoints included time to local progression, objective response rate, disease control rate, toxicities, and quality of life (QOL), assessed using the EORTC QLQ-C30 before, and 0, 1, and 3 months after SABR.

Results

Overall, 40 consecutive patients received SABR on 62 lesions between 2021 and 2022. The most common locations for OMD were the lungs (48.4%), lymph nodes (22.6%), and bone (17.7%). After a median follow-up of 15.5 months, the 2-year OS was 80%. Median PFS was 5.3 months, with 1- and 2-year rates of 21.2% and 0%, respectively. A shorter time to OMD from the controlled primary independently correlated with PFS (p=0.039, hazard ratio 2.127) alongside age, Child–Pugh class, and α-fetoprotein (p=0.002, 0.004, 0.019). The 2-year time to local progression, objective response rate, and disease control rate were 91.1%, 75.8%, and 98.4%, respectively. Overall, 10% of the patients experienced acute toxicity, and 7.5% experienced late toxicity, with no grade 3+ toxicity. All QOL scores remained stable, whereas the patients without systemic treatments had improved insomnia and social functioning scores.

Conclusions

SABR is an effective and feasible option for oligometastatic HCC, excellently controls local tumors, and improves survival without adversely affecting QOL.

Clinical Trial Number

NCT05173610
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
木子水告完成签到,获得积分10
7秒前
香蕉觅云应助jiaximoduo采纳,获得10
8秒前
刘斌发布了新的文献求助10
9秒前
ff完成签到 ,获得积分10
9秒前
wanci应助专注洋葱采纳,获得10
11秒前
DD关闭了DD文献求助
13秒前
酥脆炸鸡排完成签到,获得积分10
13秒前
15秒前
15秒前
Ly完成签到,获得积分10
16秒前
优秀小鸽子完成签到 ,获得积分10
19秒前
专一的芒果完成签到 ,获得积分10
19秒前
mmh发布了新的文献求助10
20秒前
慕青应助仲半邪采纳,获得10
20秒前
syalonyui完成签到 ,获得积分10
20秒前
11112321321完成签到 ,获得积分10
23秒前
24秒前
佐zzz完成签到 ,获得积分10
29秒前
好好学习发布了新的文献求助10
29秒前
29秒前
31秒前
仲半邪发布了新的文献求助30
32秒前
32秒前
kais完成签到 ,获得积分10
34秒前
Tuesday完成签到 ,获得积分10
35秒前
Hanna2021发布了新的文献求助10
36秒前
科目三应助mmh采纳,获得10
40秒前
kookkiki完成签到 ,获得积分10
41秒前
42秒前
科研通AI2S应助科研通管家采纳,获得10
42秒前
42秒前
Hanna2021完成签到,获得积分10
44秒前
shen完成签到,获得积分10
44秒前
44秒前
炙热成仁发布了新的文献求助10
47秒前
47秒前
47秒前
48秒前
51秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3223779
求助须知:如何正确求助?哪些是违规求助? 2872209
关于积分的说明 8179340
捐赠科研通 2539100
什么是DOI,文献DOI怎么找? 1371152
科研通“疑难数据库(出版商)”最低求助积分说明 646021
邀请新用户注册赠送积分活动 620010